VIGIL NEUROSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.5 USD | +0.29% |
|
-4.37% | +3.55% |
Presenter SpeechMatthew Bannon (Analysts)Welcome, everyone, to the 41st Annual JPMorgan Health...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimerâs disease in genetically defined subpopulations.
Calendar
2024-06-05
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.5
USD
Average target price
16.75
USD
Spread / Average Target
+378.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.55% | 132M | |
| +44.48% | 55.07B | |
| +44.59% | 40.22B | |
| -0.86% | 41.79B | |
| -7.59% | 28.17B | |
| +12.30% | 26.28B | |
| -21.83% | 18.93B | |
| +7.15% | 13.03B | |
| +29.40% | 12.26B | |
| +25.15% | 12.21B |
- Stock Market
- Equities
- VIGL Stock
- News Vigil Neuroscience, Inc.
- Transcript : Vigil Neuroscience, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 08
